https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-august-6-2026/ 2026-08-08T18:12:27Z Pharminent en Rare Disease & Gene Therapy Digest • August 6, 2026 2026-08-08T18:12:24Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-august-8-2026/ 2026-08-08T18:05:29Z Pharminent en Week in Review • INTELLIGENCE BRIEF • August 8, 2026 2026-08-08T18:05:26Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-august-1-2026/ 2026-08-08T17:42:33Z Pharminent en Week in Review • INTELLIGENCE BRIEF • August 1, 2026 2026-08-08T17:42:31Z Blog https://pharminent.com/replimune-readies-launch-of-newly-approved-melanoma-therapy-tudriqev/ 2026-08-07T20:35:23Z Pharminent en Replimune Readies Launch of Newly Approved Melanoma Therapy Tudriqev 2026-08-07T20:35:19Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-7-2026/ 2026-08-07T20:11:36Z Pharminent en Strategic News Watch • August 7, 2026 2026-08-07T20:11:34Z Blog https://pharminent.com/intellia-finds-genetic-suspect-for-liver-safety-signals-with-attr-gene-therapy/ 2026-08-08T17:30:20Z Pharminent en Intellia finds genetic suspect for liver safety signals with ATTR gene therapy 2026-08-07T12:48:29Z Blog https://pharminent.com/mediar-and-ono-pharmaceutical-to-develop-fibro-inflammatory-treatments/ 2026-08-08T17:36:41Z Pharminent en Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments 2026-08-07T09:54:36Z Blog